I am a board-certified physician who specializes in the treatment of infections in immunocompromised patients, whose immune systems are weakened due to cancer, cancer therapy, or infection with HIV. I’m also interested in educating trainees, allied healthcare professionals, and physicians about appropriate antibiotic selection and use through my work with the hospital’s Antibiotic Management Program (AMP).
As the founding AMP director, I work with two full-time clinical pharmacists and a data manager to oversee antibiotic use within the institution. Our goal is to improve the quality of care and resource utilization. The AMP team provides advice to prescribers on optimal selection, dose, and duration of antimicrobial therapy; educates healthcare professionals on rational antimicrobial use; and monitors antibiotic usage patterns to identify areas for improvement.
We also develop and update evidence-based antimicrobial guidelines, which are an important resource for prescribers. Finally, the AMP works closely with other services and departments within the institution, such as infection control, clinical laboratory, pharmacy, information services, and various medical and surgical oncology services.
My research interests are related to antimicrobial stewardship and include examining stewardship methods to optimize antimicrobial use (for example, a multicenter study evaluating post-prescription review and feedback); the relationship between antimicrobial exposure and outcomes (such as the impact of peritransplant prophylaxis on bloodstream infections in patients who have undergone allogeneic hematopoietic stem cell transplants and the prognostic implications of HIV-infected women on concomitant antiretroviral therapy and chemotherapy for breast cancer); and the interplay between microbiological testing and antimicrobial prescribing (for example, how blood culture incubation time affects time-to-antifungal administration in cancer patients with fungal infections in the blood). I’m also studying drug utilization, such as linezolid and the time-to-engraftment in HSCT patients and voriconazole and liver toxicity in HSCT patients.
- Clinical Expertise: Infectious Diseases; Immune Deficiencies
- Languages Spoken: English
- Education: MD, University of North Carolina at Chapel Hill School of Medicine
- Residencies: Beth Israel Hospital/Harvard Medical School
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Infectious Diseases
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Susan K. Seo
- A Phase I Study of Intratumoral Clostridium novyi-NT Spores in Patients with Persistent Solid Tumors
- A Phase II Study Assessing the Effectiveness of a New Vaccine for Preventing Shingles in Patients Who Had an Autologous Stem Cell Transplant
- A Phase III Study of CMX001 versus Placebo to Prevent Cytomegalovirus (CMV) Infection in Stem Cell Transplant Recipients Already Exposed to CMV